论文部分内容阅读
机体DNA修复系统如核苷酸切除修复在维持基因组功能整体性、修复致癌因素所致的损伤及抗癌过程中有着重要作用。一些核酸修复基因,如切除修复交叉互补基因1(ERCC1)及人类着色性干皮病基因D(XPD/ERCC2)的水平下降,可能会成为某种或某几种肿瘤的易感因素;但如果此种基因的水平较高,修复损伤的能力提高,对化疗药物所致基因损伤的修复能力也就增强了,那么可能对化疗药物产生耐药现象。以上两种基因的单核苷酸多态与以DDP、5-FU为基础的化疗方案的疗效存在一定关系,而消化道肿瘤又多应用铂剂及5-FU治疗,故本文对ERCC1、XPD/ERCC2与几种常见消化道肿瘤的发生及其化疗疗效的关系予以综述。
Body DNA repair systems such as nucleotide excision repair play an important role in maintaining the integrity of genomic functions, repairing damage caused by carcinogenic factors and anti-cancer process. The decreased levels of some nucleic acid repair genes, such as the excision repair cross-complementing gene 1 (ERCC1) and the human chromosomal dry skin disease gene D (XPD / ERCC2), may be susceptible to one or several tumors; however, if Such a high level of genes, the ability to repair damage increased, the repair of gene damage caused by chemotherapy drugs will also be enhanced, then the drug may be resistant to chemotherapy phenomenon. The single nucleotide polymorphisms of these two genes have some relationship with the efficacy of chemotherapy regimen based on DDP and 5-FU, and the treatment of gastrointestinal cancer with platinum and 5-FU is more and more. Therefore, / ERCC2 with several common gastrointestinal tumors and the relationship between the efficacy of chemotherapy are reviewed.